Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Anti-tumor Activity Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Next Previous
X
Search
Trial Profile

A Phase 1/2a Open-Label, Dose-Escalation/Dose-Expansion Safety, Tolerability and Anti-tumor Activity Study of IMX-110 in Combination With Tislelizumab in Patients With Advanced Solid Tumors

Status: Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 10 Aug 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs IMX-110 (Primary) ; Tislelizumab (Primary)
  • Indications Colorectal cancer; Solid tumours
  • Focus Adverse reactions
  • Acronyms IMMINENT-01
  • Sponsors Immix Biopharma

    • Most Recent Events

    • 17 Jul 2023 Second interim results (As of 7 July 2023; n=3) presented in an Immix Biopharma Media Release.
    • 26 Jun 2023 According to an Immix Biopharma media release, lead TSTx asset IMX-110, is currently in Phase 1b/2a clinical trials as a monotherapy and IMMINENT-01 combination clinical trial with BeiGenes anti-PD-1 antibody tislelizumab, holds Orphan Drug Designation (ODD) and Rare Pediatric Disease Designation (RPDD) by the FDA.
    • 14 Jun 2023 According to an Immix Media Release, the company announced that it has completed its previously announced at-the market equity offering program. It has completed 5 million dollars common stock offering. It intends to use net proceeds from the ATM offering for its IMX-110 plus tislelizumab phase 1b combination clinical trial, its IMX-110 monotherapy clinical trial and general corporate purposes.
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top